DDInter477 DDInter542
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed d
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
Dicoumarol (Compound) resembles Phenprocoumon (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene)
Dicoumarol (Compound) downregulates P4HTM (Gene)